Ablynx initiates Phase IIb RESPIRE study of ALX-0171 to treat RSV infection

Belgium-based biopharmaceutical company Ablynx has initiated its Phase IIb RESPIRE study of ALX-0171 to treat respiratory syncytial virus (RSV) infection.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news